This phenotypic shift indicates that NY-ESO-1 TCR-transduced CD8+ effector T cells may engage in tumor targeting through both antigen-specific mechanisms mediated by the NY-ESO-1 TCR and antigen-independent mechanisms analogous to those employed by NK cells. The gene discussed is CD8A; the disease is neoplasm.